# What to check before choosing joint care *What to Check — Regenerative Medicine Chandler* > Plain checks for anyone searching regenerative medicine near me: what to ask, what to bring, and how to spot a claim that goes too far. Your hip may ache through the grocery store but settle once you sit. That useful detail says more than a polished sales claim. ## What to check after searching regenerative medicine near me A clinic may call non-surgical care made from your blood or tissue regenerative treatments. That broad name alone doesn't tell you what the clinic will use. Ask what goes into the finished treatment and how the blood or tissue is handled. Then ask whether people with similar soreness were studied using that exact kind. Be wary of anyone who says worn cartilage will return. Human research hasn't shown dependable rebuilding of an arthritic joint after these treatments. A promise of certain relief also goes too far. The same care may help one person and do little for another. ## What to bring for a useful visit Write down every medicine you take and carry reports from earlier care. An old X-ray can help the doctor see how the joint has changed. Note where the ache starts and what eases it. Include trouble with sleep, stairs, walking, reaching, or getting dressed. Tell the doctor about exercise, therapy, and other care you have tried. Your experience shows what helped, what failed, and what caused more soreness. Pick a daily goal that you can describe without a score. Walking to the mailbox gives the doctor a clearer goal than asking for a new joint. ## What to expect from an honest answer The doctor may test motion, strength, swelling, and each tender area. You may stand, walk, bend, or reach during the exam. An honest answer may favor waiting or trying other care first. It won't call every sore joint right for the same treatment. Ask for the full cost before you agree. Check whether the quoted price includes later visits or added care. Unless you need urgent help, give yourself time before agreeing. A good visit leaves you informed rather than rushed. ## Sources 1. A dual systematic review compared the RCT evidence on injectable orthobiologics for knee OA with how news media describe it. Of 14 qualifying RCTs, 8 showed significant pain improvement and 10 function improvement, with frequent heterogeneity and risk of bias. Of 124 news articles: 79.0% highlighted benefits, only 29.8% mentioned drawbacks, 37.1% used the term 'stem cell' without specifying the product, 35.5% mentioned commercial entities with no disclosure, and 66.1% were favourable in tone. The authors conclude this disconnect encourages unrealistic expectations. Zhang EJX, et al. — [Disparities in Evidence and Media Portrayal of Injectable Orthobiologics for Knee Osteoarthritis: A Systematic Review of Randomized Trials and News Media.](https://pubmed.ncbi.nlm.nih.gov/42221207/). *Orthopaedic journal of sports medicine*, 2026. DOI: 10.1177/23259671261443876. 2. A Level-1a systematic review of 87 randomized PRP-for-knee-OA trials (7,925 patients, 8,118 knees) scored them against the 23-item MIBO reporting checklist. The overall MIBO score was 72%, 71% of studies scored below 80%, and reporting was worst on exactly the items that define the product: whole-blood characteristics (20%), platelet recovery rate (22%), PRP analysis (30%), PRP activation (47%). Adherence did not improve after MIBO was published. Much of the PRP literature does not say what was actually injected. Nakagawa HF, et al. — [Systematic Review of Randomized Controlled Trials Evaluating the Use of Platelet-Rich Plasma for Knee Osteoarthritis: Adherence to Minimum Information for Studies Evaluating Biologics in Orthopaedics.](https://pubmed.ncbi.nlm.nih.gov/39754417/). *The American journal of sports medicine*, 2025. DOI: 10.1177/03635465241249996. 3. In January 2025 the Federal Trade Commission banned the co-founders of a stem cell institute and their companies from marketing stem cell treatments and ordered them to pay more than $5.1 million in refunds and civil penalties. Deceptive EFFICACY ADVERTISING, not merely unapproved manufacturing, is independently actionable - the FTC polices what a clinic promises as well as what it injects. US Federal Trade Commission — [Stem Cell Institute Co-Founders and Companies Banned from Marketing Stem Cell Treatments and Ordered to Pay More Than $5.1 Million for Refunds and Civil Penalties](https://www.ftc.gov/news-events/news/press-releases/2025/01/stem-cell-institute-co-founders-companies-banned-marketing-stem-cell-treatments-ordered-pay-more-51). *FTC Press Release*, 2025. 4. A cross-sectional study contacted 273 of 317 US centres offering direct-to-consumer stem-cell therapy, posing as a 57-year-old man with knee osteoarthritis. The mean advertised price of a unilateral same-day stem-cell knee injection was $5,156 (SD $2,446), and centres claimed a mean clinical efficacy of 82% (SD 9.6%) - a figure with no support in the published evidence. The gap between the quoted number and the trial data is the single most useful thing a patient can be told before a consultation. Piuzzi NS, et al. — [The Stem-Cell Market for the Treatment of Knee Osteoarthritis: A Patient Perspective.](https://pubmed.ncbi.nlm.nih.gov/28738432/). *The journal of knee surgery*, 2018. DOI: 10.1055/s-0037-1604443. 5. FDA's guidance on the 21 CFR 1271.10(a) criteria of MINIMAL MANIPULATION and HOMOLOGOUS USE is the rule that decides whether a cell or tissue product may be offered as a lightly-regulated 'section 361' HCT/P or requires full drug approval as a 'section 351' biologic. Docket FDA-2017-D-6146; the revised July 2020 version extended the agency's period of enforcement discretion through 31 May 2021 - which has now expired, so products outside 361 need an approved application or an active IND. US Food and Drug Administration, CBER and CDRH — [Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimal). *FDA*, 2020. 6. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products. US Food and Drug Administration, Center for Biologics Evaluation and Research — [Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes). *FDA*, 2020. ## What to do when the joint stays sore QC Kinetix offers a consultation at no charge at its Chandler clinic on South Dobson Road. A medical provider will examine your joint, review earlier care, and discuss regenerative treatment options that may fit. Take your medicines and old reports, then ask about likely relief, recovery, limits, and full cost. You can go home and decide after you have those answers. Schedule a free consultation: --- Clear help when a joint stays sore. Plain help for joint soreness in Chandler, from easy home measures to warning signs and non-surgical care. Plain facts about aching joints, simple measures, danger signs, and non-surgical choices in Chandler. This site is operated by the owners of the QC Kinetix clinics in the Phoenix area, including the Chandler location at 1100 S. Dobson Rd., Suite 210. It is a commercial publication and carries no reviews, ratings or patient stories. © 2026 The Word and the Evidence · Chandler, Arizona. Educational content only, not medical advice about your particular joint.